Ranibizumab (& biosimilar Ongavia)
- BNF:
- 11.8.2
- Status:
- Do Not Prescribe (DNP), Red
- Decision Date:
- None
Comments
RED:
- NICE TA155: treatment of age-related macular degeneration (decision date - 2008)
- NICE TA274: treating diabetic macular oedema (decision date - March 2013)
- NICE TA283: treating visual impairment caused by macular secondary to retinal vein occlusion (decision date - July 2013)
- NICE TA298: treating chorodial neovascularisation associated with pathological myopia (decision date - December 2013)
DO NOT PRESCRIBE (DNP):
- NICE TA637: diabetic retinopathy (terminated appraisal) (Decision date - July 2020)
Do Not Prescribe (DNP) Drug Classifications
- 6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
search again